Japanese recommendation takes Sanwa's anagliptin closer to first market
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyusho/Kowa's anagliptin (SK-0403) has moved a step closer to becoming the sixth DPP-4 inhibitor to be launched in Japan following a positive approval recommendation for the treatment of type 2 diabetes.